RHHBY Roche Holding Ltd ADR (Sponsored)

41.2
-1.19  -3%
Previous Close 42.39
Open 42.16
Price To Book 9.86
Market Cap 282,157,791,626
Shares 6,848,490,088
Volume 2,152,251
Short Ratio
Av. Daily Volume 1,193,600
Stock charts supplied by TradingView

NewsSee all news

  1. Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

    Basel, 24 January 2020 – Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its

  2. Roche's Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy

    Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMANo treatment related safety findings leading to withdrawal seen in any risdiplam trial to

  3. European Commission approves Roche's Polivy for people with previously treated aggressive lymphoma

    Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse

  4. Roche and Illumina partner to broaden patient access to genomic testing

    Partnership to leverage Illumina's extensive decentralised installed base with Roche's expertise in assay development and to provide broad access to clinical oncology next-generation sequencingComprehensive genomic

  5. Tamiflu Fraud Bilked $1.5 Billion from Government, Alleges Whistleblower

    BALTIMORE, Jan. 13, 2020 /PRNewswire/ -- Drug company Hoffmann-La Roche (OTC:RHHBY) bilked U.S. federal and state governments out of $1.5 billion by misrepresenting clinical studies and falsely claiming that its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to enrol through to completion - November 14, 2019.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data met primary endpoint - November 11, 2019. Data to be presented at the International Scientific Congress on Spinal Muscular Atrophy. CC on February 6, 2020 at 9am EST.
Risdiplam - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
FDA approval announced May 6, 2019.
Kadcyla (KATHERINE)
HER2-positive breast cancer - residual invasive disease
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
PDUFA date May 24, 2020 under priority review. Top-line results from the pivotal portion of the open label FIREFISH trial are due 1Q 2020.
Risdiplam (RG7916)
Spinal Muscular Atrophy (SMA) Type 1
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
FDA approval announced March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 3, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 trial met primary endpoint - December 13, 2019.`
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data at ESMO noted HR 0.43. PFS 34.8 months vs 10.9 months for crizotinib.
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b data to be presented 11:30am PT, February 13, 2020 at ASCO GU.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 interim analysis passed.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data released October 21, 2019. OS/PFS co-primary endpoints met.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
FDA Approval announced October 18, 2019.
Baloxavir marboxil
Influenza
Phase 3 OS update at ASCO June 4, 2019 - median OS=21.0 vs 18.7 months; HR=0.86.
Tecentriq plus nab-paclitaxel - IMpassion 130
Triple-negative breast cancer
Phase 3 regulatory filing due 2020.
Idasanutlin (RG7388) - MIRROS
Acute myeloid leukemia (AML)
sBLA acceptance announced December 11, 2019. No PDUFA date supplied. Estimate August 11, 2020 based on 10-month timeline.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
FDA Approval announced September 27, 2019.
MabThera/ Rituxan (rituximab)
Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)
Phase 3 trial met primary and secondary endpoints - June 13, 2019.
Mabthera/Rituxan (rituximab) - PEMPHIX
Pemphigus vulgaris
Phase 3 data due 2020.
Ranibizumab
Neovascular Age-Related Macular Degeneration
Phase 3 trial did not meet primary endpoint - January 24, 2020.
Tecentriq - IMvigor010
Urothelial cancer
Phase 3 PFS co-primary endpoint met - August 5, 2019.
Tecentriq (atezolizumab) plus chemotherapy
Urothelial carcinoma
FDA approval announced August 15, 2019.
Entrectinib
Solid tumors - NTRK gene fusion
NDA filing acceptance announced October 30, 2019. PDUFA date not supplied. Estimate August 29, 2020.
Satralizumab
Neuromyelitis optica spectrum disorder (NMOSD)
Phase 3 trial met primary endpoint - September 12, 2019.
Tecentriq - IMpower110
Non-small cell lung cancer (NSCLC)
Phase 3 data at ESMO 2019 noted median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82.
Tecentriq IMvigor130
Urothelial carcinoma

Latest News

  1. Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

    Basel, 24 January 2020 – Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its

  2. Roche's Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy

    Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMANo treatment related safety findings leading to withdrawal seen in any risdiplam trial to

  3. European Commission approves Roche's Polivy for people with previously treated aggressive lymphoma

    Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse

  4. Roche and Illumina partner to broaden patient access to genomic testing

    Partnership to leverage Illumina's extensive decentralised installed base with Roche's expertise in assay development and to provide broad access to clinical oncology next-generation sequencingComprehensive genomic

  5. Tamiflu Fraud Bilked $1.5 Billion from Government, Alleges Whistleblower

    BALTIMORE, Jan. 13, 2020 /PRNewswire/ -- Drug company Hoffmann-La Roche (OTC:RHHBY) bilked U.S. federal and state governments out of $1.5 billion by misrepresenting clinical studies and falsely claiming that its

  6. Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

    SEATTLE, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical

  7. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta's investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At closing, Roche will pay

  8. European Commission approves Roche's Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

    Kadcyla in early breast cancer represents a new option after neoadjuvant treatment for this group of patients who are known to have a worse prognosisApproval based on KATHERINE trial data showing Kadcyla cut the risk of

  9. Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy

    Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE)

  10. Roche purchases shares in tender offer for Spark Therapeutics, Inc.

    Roche intends to complete Spark acquisition today Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche's wholly owned subsidiary

  11. Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc

      All antitrust approvals required to close the transaction received. Basel, 16 December 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the

  12. Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

    Basel, 16 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the UK Competition and Markets Authority has unconditionally cleared Roche's pending

  13. Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

    Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary

  14. Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma

    Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma             Basel, 13 December 2019 - Roche

  15. Roche's fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

    Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatmentPhase III FeDeriCa study showed non-inferior

  16. APHINITY six-year results strengthen evidence of clinical benefit with Roche's Perjeta-based regimen

    Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurrence or death,

  17. FDA Accepts Supplemental Biologics License Application for Xolair (omalizumab) for the Treatment of Nasal Polyps

    – The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids – –

  18. Roche receives CE Mark for its Accu-Chek SugarView app

    Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.It is designed to help non-insulin-dependent people with

  19. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019

    Basel, 9 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  20. Changes in the Board of Directors and the Corporate Executive Committee of Roche

    Jörg Duschmalé Basel, 9 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General

  21. New Data Demonstrate the Continued Clinical Benefit of Fixed-duration, Chemotherapy-free Venclexta-based Treatments in Chronic Lymphocytic Leukemia

    – In an updated analysis of the CLL14 study, Venclexta plus Gazyva achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukemia – – At four-year follow-up of the

  22. New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

    In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year

  23. Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas

    – Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable complete responses in people with relapsed or refractory non-Hodgkin's

  24. FDA Approves Genentech's Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

    – Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit – Genentech, a member of the

  25. Positive phase III results for Roche's satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine

    Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapySatralizumab targets the interleukin-6 (IL-6)

  26. FDA Grants Priority Review to Genentech's Risdiplam for Spinal Muscular Atrophy

    – Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA – Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY),

  27. Genentech Presents Pivotal Data Demonstrating Tecentriq in Combination With Avastin Improves Overall Survival in People With the Most Common Form of Liver Cancer

    – First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival in people with unresectable hepatocellular carcinoma compared with sorafenib – – Results will be

  28. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 22 November 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  29. Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium

    Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancerFollow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in

  30. Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

    LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche ((SIX: RO, ROG, OTCQX:RHHBY) to acquire Promedior. With this acquisition,

  31. CHMP recommends EU approval of Roche's Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

    Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer At three years, 88.3% of people treated with Kadcyla

  32. CHMP recommends conditional EU approval of Roche's Polivy for people with previously treated aggressive lymphoma

    First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cellsTargeted off-the-shelf treatment represents potential new option for people with relapsed or

  33. Roche's Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

    NOBILITY phase II study showed 40% of patients treated with Gazyva plus standard of care achieved complete renal response at Week 76, compared to 18% of patients treated with placebo plus standard of careRoche plans to

  34. Genentech's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy

    – Study demonstrated statistically significant improvements in the overall study population with Type 2 or 3 SMA – – No treatment related safety findings leading to withdrawal seen in any risdiplam trial to date – –

  35. Genentech's Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone

    —NOBILITY Phase II study showed 40% of patients treated with Gazyva plus standard of care achieved complete renal response at week 76, compared to 18% of patients treated with placebo plus standard of care— —Gazyva

  36. Harmony® Test: The first non-invasive prenatal test approved by Health Canada

    Canadian women now have access to an approved non-invasive prenatal test LAVAL, QC, Nov. 7, 2019 /CNW Telbec/ - Pregnant women can rely on the HARMONY test, the first non‑invasive prenatal test approved by Health

  37. Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting

    Ten Roche medicines will be featured in more than 70 abstracts and 21 oral presentations, across a range of 15 blood cancers and non-malignant haematological conditionsNew data for CD20-CD3 bispecific cancer

  38. Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

    – Roche to gain worldwide license to Dicerna's novel RNAi therapy currently in Phase 1 – – Dicerna to receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS – –

  39. Roche's marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA

    Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines Agency (EMA) grants

  40. FDA Accepts Genentech's Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder

    – Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS) – Genentech, a member of the

  41. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  42. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  43. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  44. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  45. Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma

    – First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer – – Data will be submitted to health

  46. Roche's Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

    First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to health authorities

  47. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  48. Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

    INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that it has again partnered with iHeartMedia, the number one audio company in the United States, to present the iHeartCountry

  49. Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

    40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate

  50. Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

    IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening or death

  51. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

  52. Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

    Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX

  53. Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)

    – Efficacy of Alecensa in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study

  54. FDA approves Roche's Rituxan (rituximab) in children with two rare blood vessel disorders

    Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitisThese two forms of vasculitis in children are

  55. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 30 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  56. Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

    New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated

  57. FDA Approves Genentech's Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders

    —Rituxan is the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis— —These two forms of vasculitis in

  58. Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

    Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy aloneData will be shared with

  59. Genentech's Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer

    – Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone – – Data will be shared

  60. Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

    The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapyThe

  61. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  62. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  63. Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

    First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancerFirst results from the BFAST study testing Foundation Medicine's FoundationOne®

  64. FDA approves cobas Babesia, Roche's first whole blood test for donor screening

    Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseasesIf undetected, Babesia infection can be fatal in

  65. Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary

    Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world's first comprehensive primary healthcare facility on railPhelophepa has touched the lives

  66. FDA grants Breakthrough Therapy Designation for Roche's Gazyva (obinutuzumab) in Lupus Nephritis

    There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people

  67. FDA Grants Breakthrough Therapy Designation for Genentech's Gazyva (Obinutuzumab) in Lupus Nephritis

    —There are currently no FDA-approved medicines for lupus nephritis— —The designation is based on the results of the Phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people

  68. Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running

    Roche ranked second in the 2019 Dow Jones Sustainability IndicesThe ranking acknowledges Roche's commitment to sustainability as an integral part of its business strategyCompared to 2018 Roche significantly improved

  69. Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started

  70. Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis

    Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started

  71. Roche's fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

    New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatmentData will be submitted to health authorities around the world, including the US Food and

  72. Genentech's Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer

    - New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment - - Data will be submitted to health authorities around the world, including the

  73. Genentech's Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder

    – Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS Congress 2019 – – 74% reduction in the risk of relapse for satralizumab

  74. Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

    Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 201974% reduction in the risk of relapse for satralizumab

  75. Roche's Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

    Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet              Basel, 12 September 2019 – Roche ((SIX: RO, ROG,

  76. Genentech's Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy

    – Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY),

  77. Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS

    Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS Blood neurofilament light chain (NfL) levels were significantly lowered

  78. Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS

    – Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS and PPMS – – New data show NfL may be a biomarker for predicting future

  79. European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

    The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC)Decision based on data showing that the Tecentriq plus

  80. European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer

    Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung

  81. Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    – Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD) – – New data provide insights into

  82. Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

    – Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD) – – New data provide insights into

  83. Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS

    Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain

  84. Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent

    – BLOCKSTONE study reaches primary endpoint of fewer people testing positive for the flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo – – Xofluza may represent an

  85. Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

    BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placeboXofluza may represent an important and

  86. Genentech Presents Positive Phase III Study Results for One-dose Xofluza (Baloxavir Marboxil) in Children With the Flu

    – Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza in children and show comparable efficacy to oseltamivir – – Xofluza was administered as a one-dose oral suspension, a potentially more

  87. Roche presents positive phase III study results for one-dose Xofluza in children with flu

    Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a

  88. Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

    This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicineEach year 300,000 patients around the world are diagnosed

  89. European Commission approves Roche's Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

    The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer – an aggressive and difficult-to-treat diseaseApproval based on the Phase III

  90. OncoMyx Therapeutics, Inc. to Be Honored With an AZBio Fast Lane Award

    The Arizona Bioindustry Association (AZBio) today announced that OncoMyx Therapeutics, Inc. has been named an AZBio Fast Lane Company and will be honored on October 2, 2019 at the AZBio Awards. The National Cancer